Eden Abetu Mehari , Abebe Basazn Mekuria , Mestayet Geta , Eshetie Melese Birru
{"title":"埃塞俄比亚西北贡达尔大学综合专科医院抗凝治疗患者出血并发症的程度及其相关因素","authors":"Eden Abetu Mehari , Abebe Basazn Mekuria , Mestayet Geta , Eshetie Melese Birru","doi":"10.1016/j.tru.2023.100130","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Despite the well-established effectiveness of anticoagulants, the risk of their hemorrhagic complications withheld many patients from being maintained on anticoagulant therapy. However, there is no sufficient data on the magnitude and factors associated with anticoagulant-related hemorrhagic complications in resource-constrained settings. Thus this study aimed to assess the magnitude of hemorrhagic complications and associated factors related to anticoagulant therapy among patients at the University Of Gondar Comprehensive and Specialized Hospital.</p></div><div><h3>Methods</h3><p>A retrospective follow-up study was done on 154 individuals starting from June 2018 to June 2019 on adult patients who had completed their anticoagulant therapy at the University of Gondar specialized and comprehensive hospital. They were selected using a systematic random sampling technique among all patients who had completed their anticoagulant therapy which is heparin, warfarin, or both. A retrospective data after the initiation of anticoagulant therapy was collected. The data collection was conducted from July 1 to August 30, 2019. Bivariable and multivariable logistic regression was used to identify factors. Variables with p < 0.05 were considered statistically significant.</p></div><div><h3>Results</h3><p>Out of 154 patients who received anticoagulant therapy during the study period, more than half 83 (53.9%) of the participants were female, and the mean age of participants was 54.8 ± 21.1 years. A quarter of patients, 38 (24.7%), 95% CI (17.8, 31.6) who had been on anticoagulant therapy experienced bleeding complications. Being female (AOR = 6.12, 95% CI: 1.81, 20.71, <em>P</em> = 0.004) Aspirin use (AOR = 7.71, 95% CI: 2.24, 26.53, <em>P</em> = 0.001), type of anticoagulant (AOR = 4.94, 95% CI: 1.58, 15.49, <em>P</em> = 0.006), and number of co-morbidities(AOR = 4.99, 95% CI: 1.47, 16.95, <em>P</em> = 0.010) were found to be significantly associated with hemorrhagic complications.</p></div><div><h3>Conclusions</h3><p>Hemorrhagic complications related to anticoagulant therapy are not rare. Therefore close monitoring of coagulation profiles as well as minimization of risk factors is crucial and needs collaborated work of all health care professionals and decision-makers.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Magnitude of hemorrhagic complications and its associated factors among patients on anticoagulant therapy at University of Gondar Comprehensive and Specialized Hospital, Northwest Ethiopia\",\"authors\":\"Eden Abetu Mehari , Abebe Basazn Mekuria , Mestayet Geta , Eshetie Melese Birru\",\"doi\":\"10.1016/j.tru.2023.100130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Despite the well-established effectiveness of anticoagulants, the risk of their hemorrhagic complications withheld many patients from being maintained on anticoagulant therapy. However, there is no sufficient data on the magnitude and factors associated with anticoagulant-related hemorrhagic complications in resource-constrained settings. Thus this study aimed to assess the magnitude of hemorrhagic complications and associated factors related to anticoagulant therapy among patients at the University Of Gondar Comprehensive and Specialized Hospital.</p></div><div><h3>Methods</h3><p>A retrospective follow-up study was done on 154 individuals starting from June 2018 to June 2019 on adult patients who had completed their anticoagulant therapy at the University of Gondar specialized and comprehensive hospital. They were selected using a systematic random sampling technique among all patients who had completed their anticoagulant therapy which is heparin, warfarin, or both. A retrospective data after the initiation of anticoagulant therapy was collected. The data collection was conducted from July 1 to August 30, 2019. Bivariable and multivariable logistic regression was used to identify factors. Variables with p < 0.05 were considered statistically significant.</p></div><div><h3>Results</h3><p>Out of 154 patients who received anticoagulant therapy during the study period, more than half 83 (53.9%) of the participants were female, and the mean age of participants was 54.8 ± 21.1 years. A quarter of patients, 38 (24.7%), 95% CI (17.8, 31.6) who had been on anticoagulant therapy experienced bleeding complications. Being female (AOR = 6.12, 95% CI: 1.81, 20.71, <em>P</em> = 0.004) Aspirin use (AOR = 7.71, 95% CI: 2.24, 26.53, <em>P</em> = 0.001), type of anticoagulant (AOR = 4.94, 95% CI: 1.58, 15.49, <em>P</em> = 0.006), and number of co-morbidities(AOR = 4.99, 95% CI: 1.47, 16.95, <em>P</em> = 0.010) were found to be significantly associated with hemorrhagic complications.</p></div><div><h3>Conclusions</h3><p>Hemorrhagic complications related to anticoagulant therapy are not rare. Therefore close monitoring of coagulation profiles as well as minimization of risk factors is crucial and needs collaborated work of all health care professionals and decision-makers.</p></div>\",\"PeriodicalId\":34401,\"journal\":{\"name\":\"Thrombosis Update\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thrombosis Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666572723000019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572723000019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
摘要
背景:尽管抗凝剂的有效性已得到公认,但由于其出血并发症的风险,许多患者不愿继续使用抗凝治疗。然而,在资源有限的情况下,抗凝相关出血并发症的程度和相关因素尚无足够的数据。因此,本研究旨在评估贡达尔大学综合专科医院患者出血并发症的严重程度和与抗凝治疗相关的相关因素。方法对2018年6月至2019年6月在贡达尔大学专科综合医院完成抗凝治疗的成人患者154例进行回顾性随访研究。他们是通过系统的随机抽样技术从所有完成抗凝治疗的患者中选择的,这些患者使用肝素、华法林或两者兼而有之。回顾性收集抗凝治疗开始后的资料。数据收集时间为2019年7月1日至8月30日。采用双变量和多变量logistic回归来确定影响因素。变量p <0.05认为有统计学意义。结果研究期间接受抗凝治疗的154例患者中,女性83例(53.9%)以上,平均年龄54.8±21.1岁。四分之一接受抗凝治疗的患者,38例(24.7%),95% CI(17.8, 31.6)出现出血并发症。女性患者(AOR = 6.12, 95% CI: 1.81, 20.71, P = 0.004)阿司匹林的使用(AOR = 7.71, 95% CI: 2.24, 26.53, P = 0.001)、抗凝剂的种类(AOR = 4.94, 95% CI: 1.58, 15.49, P = 0.006)和合并症的数量(AOR = 4.99, 95% CI: 1.47, 16.95, P = 0.010)与出血性并发症显著相关。结论抗凝治疗引起的出血并发症并不少见。因此,密切监测凝血状况以及尽量减少危险因素是至关重要的,需要所有卫生保健专业人员和决策者的合作。
Magnitude of hemorrhagic complications and its associated factors among patients on anticoagulant therapy at University of Gondar Comprehensive and Specialized Hospital, Northwest Ethiopia
Background
Despite the well-established effectiveness of anticoagulants, the risk of their hemorrhagic complications withheld many patients from being maintained on anticoagulant therapy. However, there is no sufficient data on the magnitude and factors associated with anticoagulant-related hemorrhagic complications in resource-constrained settings. Thus this study aimed to assess the magnitude of hemorrhagic complications and associated factors related to anticoagulant therapy among patients at the University Of Gondar Comprehensive and Specialized Hospital.
Methods
A retrospective follow-up study was done on 154 individuals starting from June 2018 to June 2019 on adult patients who had completed their anticoagulant therapy at the University of Gondar specialized and comprehensive hospital. They were selected using a systematic random sampling technique among all patients who had completed their anticoagulant therapy which is heparin, warfarin, or both. A retrospective data after the initiation of anticoagulant therapy was collected. The data collection was conducted from July 1 to August 30, 2019. Bivariable and multivariable logistic regression was used to identify factors. Variables with p < 0.05 were considered statistically significant.
Results
Out of 154 patients who received anticoagulant therapy during the study period, more than half 83 (53.9%) of the participants were female, and the mean age of participants was 54.8 ± 21.1 years. A quarter of patients, 38 (24.7%), 95% CI (17.8, 31.6) who had been on anticoagulant therapy experienced bleeding complications. Being female (AOR = 6.12, 95% CI: 1.81, 20.71, P = 0.004) Aspirin use (AOR = 7.71, 95% CI: 2.24, 26.53, P = 0.001), type of anticoagulant (AOR = 4.94, 95% CI: 1.58, 15.49, P = 0.006), and number of co-morbidities(AOR = 4.99, 95% CI: 1.47, 16.95, P = 0.010) were found to be significantly associated with hemorrhagic complications.
Conclusions
Hemorrhagic complications related to anticoagulant therapy are not rare. Therefore close monitoring of coagulation profiles as well as minimization of risk factors is crucial and needs collaborated work of all health care professionals and decision-makers.